ABUS Cash-Secured Put Strategy

ABUS (Arbutus Biopharma Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.

ABUS (Arbutus Biopharma Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $848.8M, a trailing P/E of 5.20, a beta of 0.62 versus the broader market, a 52-week range of 2.94-5.1, average daily share volume of 2.2M, a public-listing history dating back to 2007, approximately 44 full-time employees. These structural characteristics shape how ABUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.62 indicates ABUS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 5.20 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a cash-secured put on ABUS?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current ABUS snapshot

As of May 15, 2026, spot at $4.25, ATM IV 405.20%, IV rank 100.00%, expected move 116.17%. The cash-secured put on ABUS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on ABUS specifically: ABUS IV at 405.20% is rich versus its 1-year range, which favors premium-selling structures like a ABUS cash-secured put, with a market-implied 1-standard-deviation move of approximately 116.17% (roughly $4.94 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABUS should anchor to the underlying notional of $4.25 per share and to the trader's directional view on ABUS stock.

ABUS cash-secured put setup

The ABUS cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABUS near $4.25, the first option leg uses a $4.04 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABUS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABUS shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$4.04N/A

ABUS cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

ABUS cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on ABUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on ABUS

Cash-secured puts on ABUS earn premium while a trader waits to acquire ABUS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABUS.

ABUS thesis for this cash-secured put

The market-implied 1-standard-deviation range for ABUS extends from approximately $-0.69 on the downside to $9.19 on the upside. A ABUS cash-secured put lets a trader earn premium while waiting to acquire ABUS at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current ABUS IV rank near 100.00% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on ABUS at 405.20%. As a Healthcare name, ABUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABUS-specific events.

ABUS cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABUS alongside the broader basket even when ABUS-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on ABUS carry tail risk when realized volatility exceeds the implied move; review historical ABUS earnings reactions and macro stress periods before sizing. Always rebuild the position from current ABUS chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on ABUS?
A cash-secured put on ABUS is the cash-secured put strategy applied to ABUS (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With ABUS stock trading near $4.25, the strikes shown on this page are snapped to the nearest listed ABUS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ABUS cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the ABUS cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 405.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ABUS cash-secured put?
The breakeven for the ABUS cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABUS market-implied 1-standard-deviation expected move is approximately 116.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on ABUS?
Cash-secured puts on ABUS earn premium while a trader waits to acquire ABUS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABUS.
How does current ABUS implied volatility affect this cash-secured put?
ABUS ATM IV is at 405.20% with IV rank near 100.00%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.

Related ABUS analysis